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Preventive Cardiology and Rehabilitation 
 
Background: Despite the favourable effects of new therapeutic approaches during the 
acute phase of cardiac diseases and consequent favourable short-term outcomes, post-
acute management and long term prognosis still remain unsatisfactory. Cardiac 
rehabilitation (CR) is a multidisciplinary treatment with established beneficial effects for the 
vast majority of cardiac patients and universally considered an important aspect of 
secondary prevention. Although it has been shown to reduce both morbidity and mortality 
and it is a class I recommendation in the guidelines, its use remains still rather limited in 
Europe and in the rest of the world.  
Aim: The aim of this PhD research was to examine some aspects still little known, or 
unknown at all, in this field. In particular, the research aimed to evaluate safety and 
efficacy of a structured, exercise-based, CR in specific cohorts of patients: after 
transcatheter aortic valve implantation (TAVI), after left ventricular assist device (LVAD) 
implantation, and early after an acute myocardial infarction (AMI) in high risk subjects. 
Methods: All patients (78 TAVI, mean age 82.1±3.6 years, 42 LVAD, 63.4 ± 7.4 years, 
and 376 AMI, 64.4±12.3 years) were referred to the Institute Codivilla-Putti (in Cortina 
d’Ampezzo, BL, Italy) for a two week, in-hospital, CR training and comprehensive risk 
factors interventions early after the acute event (within two weeks TAVI and AMI, within 
two months after LVAD implantation).  
TAVI patients were compared with 80 consecutive peer patients who were admitted for CR 
in the same period after surgical aortic valve replacement (sAVR) and LVAD patients 
compared with 47 coeval chronic heart failure (CHF) patients who were admitted for CR in 
the same period after an acute heart failure event. In LVAD cohort, cardiac autonomic 
function was evaluated by means of heart rate variability. 
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AMI patients were divided into 2 groups according to a 40% left ventricular ejection fraction 
(LVEF) cut-off at enrolment, in order to evaluate the influence of a reduced LVEF on the 
rehabilitative process; furthermore, in 326 patients a glucometabolic characterization was 
obtained by means of a standard oral glucose tolerance test (OGTT) in patients without 
known diabetes.  
In all patients the training protocol consisted of a low-medium intensity exercise protocol 
developed in three sets of exercises, 6 days per week: 30 min of respiratory workout, 
followed by an aerobic session on a cyclette (or on an arm ergometer in those patients 
who were not able to cycle) in the morning and, in the afternoon, 30 min of callisthenic 
exercises. Each session was supervised by a physician and a physiotherapist and all 
patients were ECG monitored by a telemetry system. 
Functional capacity was assessed by a six min walking test (6MWT) on admission, and a 
second test at discharge; when possible, a cardiopulmonary exercise test (CPET) was 
also performed. The Barthel Index (BI) was used as an autonomy index in TAVI and LVAD 
cohorts. In AMI patients rate of death, hospitalizations, smoke cessation, physical activity 
and adherence to pharmacological treatment were recorded at follow up (up to 5 years, 
median 2 years). 
Results: Despite the high risk profile of the population, the drop out rate was quite low 
(1.3% of TAVI, 1.1% of AMI and 11.9% of LVAD patients had to be transferred due to non 
fatal complications). All the subjects who completed the program had enhanced 
independence, mobility and functional capacity (mean BI increment was 9.9±12.6, p<0.01 
and 11.9±10.5, p<0.01, in TAVI and LVAD patients respectively; mean 6MWT gain was 
60.4±46.4 mt, p<0.01, 83.2±36.0 mt, p<0.05, 70.7±55.7 mt, p<0.01, in TAVI, LVAD and 
AMI patients, respectively). 
Analysing the specific cohorts, a smaller proportion of TAVI patients, compared with sAVR, 
was able to complete at least a 6MWT (82% vs 92%) or a CPET (61% vs 95%) but, in 
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those who did, the distance walked at 6MWT at discharge did not significantly differ 
between the groups (272.7±108 vs. 294.2±101 mt, p=0.42), neither did the exercise 
capacity assessed by CPET (peak-VO2 12.5±3.6 vs. 13.9±2.7 ml/kg/min, p=0.16).  
At the end of the program, physical performance in LVAD patients was still generally poor, 
but not dissimilar from that found in CHF patients (peak-VO2 reached at CPET was 
12.5±3.0 vs. 13.6±2.9 ml/kg/min, p=0.20).  
Evaluating AMI patients, subjects with LVEF<40% achieved significantly lower peak-VO2 
at CPET than the controls (15.2±3.9 vs. 18.2±5.2 ml/kg/min, p<0.01). After OGTT 
administration, a high prevalence of abnormal glucose metabolism was found (54%). As 
expected, exercise capacity was poorer in diabetic and pre-diabetic patients when 
compared with normoglicemic (peak-VO2 at CPET 15.3±4.1 vs 17.9±4.8 vs 19.4±5.5 
ml/kg/min, p<0.01). At follow up 73% of the subjects reported to exercise regularly, 77% of 
the smokers definitively quitted and a high adherence to the therapy was registered. 
Cardiac and all cause mortality resulted 5.0% and 8.0 % at 1 year and 8.0 % and 13.0 % 
at 5 years, respectively and resulted higher in older people and in those with lower LVEF. 
Conclusions: Patients who underwent TAVI and LVAD implantation are characterized by 
a long-term deconditioning status. In this perspective, benefit is not automatically achieved 
through high-technology interventions and pharmacological management alone. This study 
have shown that a short-term, supervised, exercise-based CR is feasible, safe and 
effective in elderly patients after TAVI, as well as after traditional surgery, and after LVAD 
implantation. An early CR programme enhances independence, mobility and functional 
capacity and should be encouraged in these subjects.  
An early and intensive CR, based on physical activity and counselling, resulted to be safe 
and effective also in high risk patients after AMI, both in the short and in the long period. 
Indeed, a significant improvement in functional capacity in the short term - independent 
from the basal ventricular function or glucometabolic status - and a high adherence to 
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therapy and to lifestyle modifications in the long term were achieved. Despite the high risk 
profile of these patients, this produced a favourable effect on cardiac and total mortality. 
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Cardiologia preventiva e riabilitativa 
 
Introduzione: Nonostante gli effetti favorevoli di nuovi approcci terapeutici durante la fase 
acuta delle malattie cardiache e conseguente prognosi più favorevole nel breve termine, la 
gestione della fase post-acuta di tali patologie e la prognosi a lungo termine rimane ancora 
insoddisfacente. La Riabilitazione Cardiologica (RC) è un trattamento multidisciplinare con 
chiari effetti benefici nella stragrande maggioranza dei pazienti cardiologici ed 
universalmente considerata un aspetto importante della prevenzione secondaria. Sebbene 
si sia dimostrata in grado di ridurre morbidità e mortalità e sia ormai un trattamento 
raccomandato in I classe nelle linee guida, il suo uso rimane ancora piuttosto limitato in 
Europa e nel resto del mondo.  
Scopo: Lo scopo del presente programma di ricerca è stato esaminare alcuni aspetti 
ancora pochi noti, se non del tutto sconosciuti, in questo campo. In particolare, la presente 
ricerca ha avuto lo scopo di valutare sicurezza ed efficacia di una RC strutturata, basata 
sull’esercizio fisico, in specifiche coorti di pazienti: dopo impianto di valvola aortica 
transcatetere (TAVI), dopo impianto di assistenza ventricolare sinistra (LVAD), e subito 
dopo infarto miocardico acuto (AMI) in soggetti ad alto rischio. 
Metodi: Tutti i pazienti (78 TAVI, età media 82.1±3.6 anni, 42 LVAD, 63.4 ± 7.4 anni, e 
376 AMI, 64.4±12.3 anni) sono stati inviati presso l’Istituto Codivilla-Putti (Cortina 
d’Ampezzo, BL, Italia) per un periodo di riabilitazione cardiologica degenziale di due 
settimane, basato sull’allenamento fisico ed interventi sui fattori di rischio cardiovascolare, 
subito dopo l’evento acuto (entro due settimane dopo TAVI ed AMI, entro due mesi dopo 
impianto di LVAD). 
I pazienti TAVI sono stati confrontati con 80 pazienti di pari caratteristiche che nello stesso 
periodo giungevano in riabilitazione dopo sostituzione valvolare aortica per via tradizionale 
(sAVR); i pazienti LVAD sono stati confrontati con 47 pazienti di pari età affetti da 
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scompenso cardiaco cronico (CHF) che giungevano nello stesso periodo dopo una 
riacutizzazione di scompenso. Nella coorte dei LVAD è stata inoltre valutata la funzione 
autonomica mediante lo studio dell’ heart rate variability. 
Per valutare gli effetti di una depressione della frazione d’eiezione del ventricolo sinistro 
(LVEF) sul processo riabilitativo, i pazienti AMI sono stati divisi in 2 gruppi in base alla 
LVEF (cut-off 40%). Inoltre, in 326 pazienti, è stata ottenuta una caratterizzazione 
glumetabolica mediante una curva da carico di glucosio standard (OGTT) somministrata ai 
soggetti senza diabete noto. 
Tutti i pazienti sono stati sottoposti ad un ciclo di ricondizionamento fisico con esercizi 
prevalentemente aerobici, distribuiti in 3 sessioni quotidiane per 6 giorni alla settimana (30 
minuti di ginnastica respiratoria, seguiti da una sessione sulla cyclette, o su un arm-
ergometro in coloro che non erano in grado di pedalare, nel pomeriggio 30 minuti di 
esercizi callistenici), sotto stretto monitoraggio telemetrico e diretta supervisione medica e 
fisioterapica. 
La capacità funzionale è stata valutata mediante six min walking test (6MWT) all’ingresso 
e alla dimissione e un test cardiopolmonare (CPET). Nelle coorti TAVI e LVAD è stata 
usata la scala di Barthel (Barthel Index, BI) per valutare il grado di autonomia. Nei pazienti 
AMI è stato registrato al follow up (fino a 5 anni, mediana 2 anni) l’incidenza di morte, 
nuove ospedalizzazioni, cessazione del fumo, attività fisica ed aderenza alla terapia. 
Risultati: Nonostante l’alto profilo di rischio della popolazione, il tasso di abbandono dal 
programma è risultato piuttosto basso (nell’ 1.3% dei pazienti TAVI, 1.1% degli AMI e 
11.9% dei LVAD si è reso necessario il trasferimento all’ospedale per acuti per 
complicazioni non fatali). Tutti i soggetti che hanno completato il programma hanno 
migliorato la propria indipendenza, mobilità e capacità funzionale (incremento medio del BI 
9.9±12.6, p<0.01 e 11.9±10.5, p<0.01, nei pazienti TAVI e LVAD rispettivamente; 
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guadagno medio al 6MWT 60.4±46.4 mt, p<0.01, 83.2±36.0 mt, p<0.05, 70.7±55.7 mt, 
p<0.01, nei pazienti TAVI, LVAD and AMI, rispettivamente).  
Analizzando le specifiche coorti, una percentuale più bassa di pazienti TAVI rispetto a 
quelli del gruppo sAVR sono stati in grado di completare almeno un 6MWT (82% vs 92%) 
o un CPET (61% vs 95%) ma, in coloro che vi sono riusciti, non vi erano differenze 
significative tra i due gruppi in termini di distanza percorsa al 6MWT alla dimissione 
(272.7±108 vs 294.2±101 mt, p=0.42) e capacità funzionale al CPET (VO2 al picco 
12.5±3.6 vs 13.9±2.7 ml/kg/min, p=0.16).  
Al termine del programma la performance fisica nei pazienti LVAD era generalmente 
scarsa, ma non dissimile da quella dei pazienti CHF (VO2 al picco al CPET 12.5±3.0 vs 
13.6±2.9 ml/kg/min, p=0.20).  
Tra i pazienti AMI, coloro con LVEF<40% hanno raggiunto al CPET un VO2 al picco 
dell’esercizio significativamente più basso rispetto ai controlli (15.2±3.9 vs 18.2±5.2 
ml/kg/min, p<0.01). Dopo somministrazione dell’OGTT è stata riscontrata un’alta 
prevalenza di alterazioni del metabolismo glucidico non precedente note (54%). Come 
atteso la capacità fisica era inferiore nei diabetici e nei prediabetici in confronto ai 
normoglicemici (al CPET VO2 al picco 15.3±4.1 vs 17.9±4.8 vs 19.4±5.5 ml/kg/min, 
p<0.01). Al follow up 73% dei soggetti hanno riferito di svolgere un’attività fisica regolare, 
77% dei fumatori hanno definitivamente smesso ed è stata registrata un’alta aderenza alla 
terapia. La mortalità cardiaca e per tutte le cause è risultata 5.0% e 8.0% ad 1 anno, 8.0% 
e 13.0% a 5 anni, rispettivamente, ed è risultata più elevata nei soggetti più anziani ed in 
quelli con ridotta LVEF. 
Conclusioni: I pazienti che sono andati incontro ad intervento di TAVI e LVAD sono 
caratterizzati da un notevole grado di decondizionamento fisico. In tale prospettiva non si 
può automaticamente raggiungere un beneficio con il solo intervento ad alta tecnologia o 
con il trattamento farmacologico. Un breve periodo di RC, con supervisione medica, si è 
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dimostrato fattibile, sicuro ed efficace in pazienti anziani dopo TAVI, così come dopo 
chirurgia aortica tradizionale, e dopo impianto di LVAD. Un programma precoce di RC 
aumenta l’indipendenza, la mobilità e la capacità funzionale ed andrebbe sicuramente 
incoraggiato in questi soggetti. 
Una RC intensiva e precoce basata sull’attività fisica e sul counselling è risultata sicura ed 
efficace anche in soggetti ad alto rischio dopo AMI, sia nel breve che nel lungo termine. 
Infatti è stato raggiunto un significativo miglioramento della capacità funzionale nel breve 
periodo - indipendentemente dalla funzione ventricolare sinistra residua o dallo stato 
glucometabolico - ed un’elevata aderenza alla terapia e alle modifiche dello stile di vita 
proposte. Nonostante l’elevato profilo di rischio di tali pazienti, questo può aver prodotto un 
effetto favorevole sulla mortalità. 
 
 
 
Keywords: cardiac rehabilitation, preventive cardiology, exercise capacity, six minute 
walking test, cardiopulmonary exercise test, outcome, transcatheter aortic valve 
implantation, left ventricular assist device,  myocardial infarction. 
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Introduction 
 
Despite the favourable effects of new therapeutic approaches during the acute phase of 
cardiac diseases and consequent favourable short-term outcomes, post-acute 
management and long term prognosis still remain unsatisfactory. Indeed cardiac diseases 
are still the leading causes of death in industrialized countries. They also induce 
considerable harm to survivors and often lead to severe and irreversible physical and 
neurological disabilities. 
Cardiac rehabilitation (CR) is defined as “a multifaceted and multidisciplinary intervention 
witch aim to limit the adverse physiological and psychological effects of cardiac illness, to 
reduce morbidity and mortality, and to enhance the patient’s psychosocial and vocational 
status”.1,2 Its beneficial effects are established for the vast majority of cardiac patients and 
it is universally considered an important aspect of secondary prevention.3,4 Referral for CR 
is a class I indication (useful and effective) in most contemporary clinical practice 
guidelines, including those for ST-segment elevation myocardial infarction (MI),5 unstable 
angina/non-ST-segment elevation MI,6 coronary artery bypass graft (CABG) surgery,7 
valvular heart disease,8 heart failure,9 peripheral arterial disease.10  
Contemporary cardiac rehabilitation can be divided into three phases. Each phase aims to 
facilitate recovery and to prevent further cardiovascular disease. Phase I, or inpatient 
phase, is initiated while the patient is still in the acute care hospital. It consists of early 
progressive mobilization of the stable cardiac patient to the level of activity required to 
perform simple household tasks. The shorter hospital stay with modern cardiology makes 
it difficult to conduct formal inpatient education and training programs. Thus inpatient 
cardiac rehabilitation programs are mostly limited to early mobilization to make self care 
possible by discharge, and brief counselling about the nature of the illness, the treatment, 
risk factors management and follow-up planning. In most countries, among which the USA,  
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phase II is a supervised ambulatory outpatient program of 3 to 6 months duration which 
consists of outpatient monitored exercise and aggressive risk factor reduction. In Europe 
residential programs of 2 to 4 weeks duration are offered. In Italy both these realities 
coexist: lower risk patients usually are referred to out-patients programs and higher risk 
ones are referred to residential programs. This phase is managed in specialized centres 
by a multidisciplinary team comprehending cardiologists, physiotherapists, psychologists, 
nutritionists. Phase III is a lifetime maintenance phase in which physical fitness and 
additional risk-factor reduction are emphasized. It consists of home-or gymnasium-based 
exercise with the goal of continuing the risk factor modification and exercise program 
learned during phase II.11 
Historical perspectives. The relative importance of physical activity for patients with so-
called "disorders of the chest" was noted some 200 years ago. In 1772, Heberden 
published a report describing a six-month exercise program consisting of 30 minutes of 
daily sawing activity for one of his male patients who had a diagnosed chest disorder.12 
Parry, in 1799, independently noted the beneficial effects of physical activity in his patients 
who suffered from chest pain.13 Although these reports were written long before any formal 
recognition or definition of coronary artery disease, undoubtedly some of these patients 
had experienced anginal disease or myocardial infarctions. This initial, apparently positive 
attitude toward physical activity was all but forgotten by the time Herrich, in 1912, gave his 
original clinical description of an acute MI.14 Expressed concern regarding physical 
exertion and the increased risk of ventricular aneurysm rupture or heightened arterial 
hypoxemia precipitated the adoption of a conservative treatment approach in which 
patients were kept at bed rest for six to eight weeks post-MI. Pharmacological 
management of cardiac patients was limited. The agents most commonly used were 
digitalis and nitroglycerin. The traditional medical management of physical inactivity for 
coronary patients was reinforced in the 1930s by two physicians, Mallory and White.14 
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They found that the necrotic myocardial region transformed into scar tissue after about six 
weeks. Therefore, they advised a minimum of three weeks in bed for patients with even 
the smallest MI.14 Continued limited physical activity was prescribed after patient hospital 
discharge. Stair climbing often was prohibited in some cases for up to a year. During this 
so-called convalescent period, the patient's tendency to become an invalid was enhanced. 
Follow-up medical management gave little advice to patients regarding functional cardiac 
capacity, stress management, or education about the disability and its limitations. 
Frequently, patients did not return to work and soon were considered as nonproductive 
members of society. Research during the first three decades of the twentieth century 
focused mainly on better methods of diagnosing and classifying cardiac disorders and 
simple testing for "circulatory efficiency”.15 Little emphasis was placed on the actual 
development or evaluation of the rehabilitation program.  
By the late 1930s, many members of the labour force were retired on disability because of 
cardiac problems. The New York State Employment Service, concerned about the growing 
numbers of men on disability, decided to investigate the situation. A survey identified that 
80% of the individuals receiving disability were coronary patients who had not returned to 
their jobs. Furthermore, only 10% had attempted either to retrain for another job or seek a 
different position in their company. In 1940, the New York State Employment Service 
asked the New York Heart Association to assist in evaluating cardiac workers to determine 
the level of activity the cardiac patient could perform safely. This request eventually led to 
the establishment of the Work Classification Unit or Work Evaluation Unit.16 Cardiac work 
evaluation units were located in teaching hospitals, rehabilitation centres, and community 
hospitals. Patients were referred by private physicians and employers and from institutions 
and vocational agencies. At the unit, patients were evaluated for their physical and 
psychological capacity for work. Cardiologists performed laboratory tests, resting ECGs, 
and a Masters Step Test. Most evaluations took three weeks to complete and, after a team 
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conference, recommendations were made to the referring party. No formal exercise 
program was included or prescribed for the patients. Thus, the cardiac work evaluation unit 
was an early approach to what we know today as cardiac rehabilitation.16 Criticism grew, 
however, in the 1950s over the small numbers of patients being referred and the methods 
used to classify coronary disability. This situation caused fragmentation of evaluation and 
care of these patients. Gradually, the effectiveness and success of the units dwindled.  
In 1952, Levine and Lown openly questioned the need for enforced bed rest and 
prolonged inactivity after an MI. Based on work performed in a Boston hospital during the 
1940s and spurred by the manpower needs during World War II, they helped liberalize the 
attitudes among physicians regarding the need for rigid restrictions of activity. From their 
work, they concluded that long-continued bed rest "decreases functional capacity, saps 
morale, and provokes complications”.17 Their report caught the attention of many and 
raised numerous clinical questions about the management of cardiovascular disease. At 
the Thirteenth Scientific Session of the American Heart Association (AHA) in Chicago in 
1953, the noted physician Louis Katz told the medical community that "physicians must be 
ready to discard old dogma when they are proven false and accept new knowledge”.18 The 
need to continue research on physical activity and to assimilate this new information into 
the practice scheme for the cardiac patient was emphasized. Turell and Hellerstein urged 
physicians to provide a more positive philosophy and a more comprehensive approach in 
treating cardiac patients.19 The application of work physiology principles was stressed. 
They recommended a graded step program (a prototype to contemporary cardiac 
rehabilitation) based on established energy requirements of physical activity and patient 
exercise tolerance with continual evaluation of cardiovascular function. Thus, the 
prevailing theme of this period was clinical research on physical activity and its relationship 
to coronary artery disease. The strength of the new research provided visible evidence to 
a doubting medical society. Dwight Eisenhower, then President of the United States, 
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suffered a heart attack in office. His physician was the noted Paul Dudley White, a man 
strongly committed to the positive effects of exercise. He prescribed graded levels of 
exercise, including swimming, walking, and golf, for his celebrated patient. This regimen 
was viewed by many physicians as reckless and inappropriate, especially given the 
patient's eminence. The result turned out to be so positive for President Eisenhower that 
he created the President's Youth Fitness Council, later to be renamed the President's 
Fitness Council by President Kennedy.16  
By the 1960s, numerous studies demonstrated that early activity after an MI safely 
negates the adverse effects associated with prolonged bed rest. Saltin et al20 reported that 
the functional capacity of normal subjects confined to bed for three weeks decreased 
approximately 33%. Equally important was his finding that an appropriate equal time of 
training was necessary to restore the subjects to their prebed-rest condition. After three 
months of twice-daily rigorous exercise programs, all patients exceeded their control 
states. Inpatient cardiac rehabilitation became more formalized in the sixties primarily 
through the efforts of Wenger21 and Zohman,22 and Bruce23 in the fifties. The adopted 
programs instituted early supervised reconditioning during the acute post-MI phase while 
the patient was still in the Coronary Care Unit (CCU) and during the post-acute phase 
while the patient was in the step-down unit. The protocol of Wenger et al consisted of a 14-
step program of progressively increasing physical activity levels with emphasis in three 
areas: graded physical exercises, activities of daily living, and educational activities.21 The 
program usually was initiated in the CCU after the patient's clinical condition was stable. 
Physical activities at this stage required low-level oxygen demand. They included self-care 
and supervised active and passive range of motion exercises; progressive ambulation was 
added shortly thereafter. Patient and family education programs paralleled the graded 
physical activities. This structured plan greatly assisted the patient toward discharge and 
an early return to normal living. Zohman's program provided exercise using an equicaloric 
 18 
technique that matched the level of energy expenditure with exercise of equal caloric 
value.22 The exercises were monitored by radiotelemetry, and energy costs were 
measured as a check on the rehabilitation activities. The favourable outcome of these 
structured programs encouraged the development of other similar programs around the 
USA. Soon, other hospitals also were experiencing the positive economic implications of 
early intervention. These included a hastened recovery time and decreased hospital stay; 
improved functional status at the time of discharge; and in turn, an earlier return to work.  
By the end of the 1960s, Hellerstein encouraged by the results of his inpatient program, 
boldly chose to incorporate physical exercise into a follow-up program after hospital 
discharge. A formalized study was conducted involving 200 post-MI patients at the 
Cleveland YMCA and later at the local Jewish Community Center.24 Hellerstein was 
criticized severely by his peers for his innovative but risky approach. The study clearly 
demonstrated that cardiac patients could benefit physiologically from regular progressive 
exercise and enjoy improved psychological confidence without a negative effect on either 
mortality or morbidity.24 The success of this medically supervised program offered a new 
dimension, the outpatient program, to cardiac rehabilitation. As a result of the work of 
Hellerstein, Wenger, Zohman, and others, the concept of progressive supervised activity 
for the post-MI patient and the post-surgical patient has taken its rightful role in the 
practice of medical therapeutics. 
Nowadays, despite the role of CR having been extensively documented, endorsed and 
promoted by a number of health care organizations and their position statements for the 
comprehensive secondary prevention of cardiovascular events, its use remains still rather 
limited in Europe and in the rest of the world.25 
Aim. The aim of this PhD research was to examine some aspects still little known, or 
unknown at all, in the CR field. In particular, the research aimed to evaluate safety and 
efficacy of a structured, exercise-based, CR in specific cohorts of patients: after 
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transcatheter aortic valve implantation (TAVI), after left ventricular assist device (LVAD) 
implantation, and early after (within 2 weeks) an acute myocardial infarction (AMI) in high 
risk subjects. 
CR after TAVI. Due to the significant increase in the life span, nowadays degenerative-
calcific aortic stenosis (AS) is the most common acquired valvular heart disease in the 
developed countries, affecting 2-7% of the population aged over 65 years.8 
Once symptoms occur in severe AS, the prognosis is very poor without treatment with a 
mortality rate up to 50-60% after 2 years; surgical aortic valve replacement (sAVR) is 
currently the gold standard treatment for these patients26 but about 30% of them are 
declined for surgery because of their high or prohibitive surgical risk.27 
Transcatheter aortic-valve implantation (TAVI) is an innovative procedure, in which a 
bioprosthetic valve is inserted through a catheter and implanted within the diseased native 
aortic valve; at the moment, two models with substantial clinical data are available: the 
balloon-expandable Edwards SapienTM and the self-expanding Medtronic CoreValveTM.28 
Since 2002, when the procedure was first performed,29 there has been a rapid growth in its 
utilization throughout the world and now data from large European observational registries 
- reporting both improved procedural success and mid-term survival - are available.30,31 
After results from the randomized Placement of AoRTic TraNscathetER Valves 
(PARTNER) trials, TAVI represents now the standard of care for extremely high risk or 
‘inoperable’ patients and it is a valid alternative to surgery for selected high-risk but 
‘operable’ patients with symptomatic AS.32,33 
All patients after TAVI, because of their age and primary compromised conditions, are 
natural candidates for referral to exercise based CR; despite this, until now no data have 
been available about the safety and the efficacy of a comprehensive rehabilitative period in 
these subjects. 
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CR after LVAD implantation. In the last decade there was an expanding application of 
left ventricular assist devices in end-stage chronic heart failure patients, due to a shortage 
of donor organs combined with the efficacy of these mechanical circulatory supports.34 The 
modern devices assist the left ventricle by means of a rotary pump applied on the left 
ventricle apex and generating a continuous axial flow from the apex of the left ventricle to 
the descending aorta. They can be applied both as temporary support (bridge to 
transplantation) or as permanent treatment in selected patients not suitable to heart 
transplantation. The positive effect of LVAD on left ventricular function (LV) include marked 
reduction in LV systolic and diastolic pressures, leading to reverse LV remodelling, a 
normalized pressure volume relation, and myocyte recovery, with improved contractile 
function. As a matter of fact LVAD recipients demonstrate improvement in exercise 
tolerance and non cardiac organ function.35,36 However many of the studies in the literature 
regarding exercise capacity after LVAD were conducted on pulsatile machines - a type of 
LVAD the use of which is almost abandoned today – and relatively late after implantation 
(at least 3 to 7 months).37,38  
Little is known about feasibility, safety and efficacy of a structure, exercise training in the 
early phase after LVAD implantation.39 
Early CR after AMI in high risk patients. In coronary artery disease (CAD) patients 
exercise-based CR has lots of valuable effects: it improves symptoms, functional capacity, 
metabolic and psychological status, reducing both morbidity and mortality.40-42 Recently, 
Martin et al.43 among 5886 individuals who had undergone CR after an acute MI showed, 
in the completers, the lowest mortality and hospitalization rates as long as the fewest 
emergency room visits versus non completers. Furthermore, a strong dose–response 
relationship has also been demonstrated between the number of CR sessions and long-
term outcomes with a lower risks of death and MI at 4 years.44 
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Even though maximal benefit of CR derives from early initiation of exercise (as early as 1 
week after MI hospital discharge),45 most of the rehabilitative programs begin too late after 
the acute event (more than one month). Furthermore the studies available in the literature 
regarding an early beginning of a structured physical activity after an acute MI were 
conducted in the pre-trombolitic era46 or consider low risk, outpatients, cohorts.47 
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Methods 
 
Patients. All patients (78 TAVI, mean age 82.1±3.6 years, 42 LVAD, 63.4 ± 7.4 years, and 
376 AMI, 64.4±12.3 years) were referred to the Institute Codivilla-Putti (in Cortina 
d’Ampezzo, BL, Italy), in the period 2008-2013, for a two week, in-hospital, CR training 
and comprehensive risk factors interventions early after the acute event (within two weeks 
TAVI and AMI, within two months after LVAD implantation). TAVI and AMI patients were 
submitted by an unique centre (University Hospital of Padova), LVAD patients were 
referred by four different institutions (Padova, n=18, 43%, Udine, n=14, 33%, Siena, n=7, 
16%, Bologna, n=3, 7%). Demography, medical history and conventional risk factors, 
physical examination and treatment data were recorded for all the patients; routine 
biochemical analyses - including haematic crasis, hepatic enzymes, serum creatinine, 
hemocoagulative pattern, lipid determination, glycated haemoglobin A1c (HbA1c) - were 
obtained on admission; a 2-D echocardiogram was performed before discharge. 
Functional capacity was assessed by a six-minute walking test (6MWT) on admission and 
at discharge and by a cardiopulmonary exercise test (CPET) at discharge, when clinically 
feasible. Safety (incidence of fatal events during in-hospital stay and complications 
requiring transfer to advanced medical unit) and effectiveness (changes in the functional 
capacity in the short term in all patients and adherence to therapy, to proposed lifestyle 
modifications and impact on prognosis in AMI patients) were considered.  
 
CR after TAVI. TAVI patients (EdwardsTM trans-apical n=16, 20%, EdwardsTM trans-
femoral n=47, 60%, CorevalveTM n=15, 20%) were compared with 80 consecutive peer 
patients who were admitted for CR in the same period after surgical aortic valve 
replacement (sAVR). All sAVR patients had received a biological prosthesis. 
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CR after LVAD. LVAD patients underwent the assist device implantation (Jarvik-2000 
Flowmaker® 33, 78%, Berlin Heart Incor® 2, 4%, Heart Ware® 7, 16%) due to end-stage 
chronic heart failure (CHF). Shortly before intervention they often were in terminal 
conditions, they needed intensive inotropic support and usually had been bedridden for 
quite a long period. As a matter of fact, these patients began the programme in extremely 
poor general conditions. During CR stay, the device rotation speed was maintained 
unmodified, as initially set by the cardiac surgery team to allow maximum support while 
avoiding suction events (range 10000-11000 rpm, corresponding to a nominal device 
output at rest of 4 to 5 l/min). LVAD patients were compared with 47 coeval advanced CHF 
patients who were admitted for CR in the same period after an acute heart failure event. In 
order to assess cardiac autonomic function in the early phase after axial-flow LVAD 
implantation, heart rate variability (HRV) was also evaluated in 24 patients (those with 
atrial fibrillation, or rhythm mainly induced by a pace-maker, or with diabetes mellitus were 
excluded). The following HRV time-domain parameters were evaluated by the means of a 
24h ECG Holter (Del Mar-Reynolds Impresario Holter Analysis System, vers. 2.8.0024): 
mean and minimum heart rate, standard deviation of all normal RR intervals (SDNN), 
square root of the mean square differences of successive NN intervals (RMSSD), standard 
deviation of the 5-min average of NN intervals (SDANN), proportion of successive beats 
with differences in NN intervals >50ms (pNN50), average of the standard deviations of all 
NN intervals for each 5-minute segments (SDNNindex) and HRV Triangular Index. The 
HRV parameters were evaluated both on the whole 24-h recording and subdivided by day 
and night.  
 
CR after AMI. All patients had an angiography-documented CAD and 84.8% had received 
a percutaneous revascularization treatment in at least one vessel. They were selected by 
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the submitting centre to our programme if they had a complicated AMI (cardiogenic shock 
or pulmonary edema, cardiac arrest, complex ventricular arrhythmias), an incomplete 
revascularization (because of clinical decision, unfavorable coronary anatomy or technical 
failure), or had at least 3 cardiovascular risk factors. Low risk patients followed an out-
patient CR programme in another centre and were excluded from this study. Coronary 
artery bypass grafting, echo- or cardiac MRI- documented intracavitary thrombosis, 
extreme thinning or suspected rupture of the ventricular wall and/or intra-myocardial 
bleeding were exclusion criteria as well. In order to evaluate the influence of a reduced left 
ventricular ejection fraction (LVEF) on the rehabilitative process, the population was 
divided into 2 groups according to a 40% LVEF cut-off at enrolment. Moreover, in 326 
patients a glucometabolic characterization was obtained by means of a standard oral 
glucose tolerance test (OGTT, 75 g anhydrous glucose in 200 ml water48) in patients 
without known diabetes. The test was performed during the 2nd week of stay in the 
rehabilitation centre, usually during the 3rd week after the acute event. The classification of 
the glucometabolic state was made according to the American Diabetes Association 
Criteria 2008:49 
- Normal Glucose Tolerance (NGT) was defined as Fasting plasma glucose 
(FPG)<100 mg/dl (5.6 mmol/L) and glycaemia at the second hour after OGTT 
(OGTT-2h) <140 mg/dl (7.8 mmol/L); 
- Impaired Fasting Glycaemia (IFG) as FPG ≥100 mg/dL (5.6 mmol/L) but <126 mg/dl 
(7.0 mmol/L); 
- Impaired Glucose Tolerance (IGT) as OGTT-2h ≥140 mg/dl (7.8 mmol/L) but <200 
mg/dl (11.1 mmol/L); 
- Newly detected Diabetes Mellitus (DM) as either FPG ≥126 mg/dl (7.0 mmol/L) or 
OGTT-2h ≥200 mg/dl (11.1 mmol/L). 
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A prediabetic condition was defined when IFG and/or IGT was present. After OGTT 
administration 3 groups could be identified in the AMI cohort: NGT, prediabetics and 
diabetics (known or newly detected).  
 
Rehabilitation programme. In all patients the training protocol consisted of a low/medium 
intensity exercise protocol developed in 3 sets of exercises, 6 days a week: 30 min of 
respiratory workout, followed by an aerobic session on a cyclette (or on an arm-ergometer 
for those patients who were not able to cycle) in the morning and, in the afternoon, 30 min 
of callisthenic exercises. Each session was supervised by a physician and a 
physiotherapist and all patients were ECG monitored by a telemetry system. Aerobic 
training was performed using a constant work rate modality without exceeding 70% of the 
maximal predicted peak heart rate (HR) for each patient.50 Each aerobic session lasted 10 
minutes at the beginning, with a 5 minutes progressive increase to reach a 30 min target; 
the exercise prescription and evaluation of exercise intensity was carefully derived from 
the subjective rating of perceived exertion, using a category ratio Borg scale.50 Individual 
and group counselling meetings, psychological and nutritional evaluation were also 
performed for all patients. 
 
Autonomy evaluation. The Barthel index (BI) was used as an autonomy index in TAVI 
and LVAD cohorts. The BI uses a scale of 0–100 to rate the degree of independence in 
activities of daily living, where 0 is total dependence and 100 is total independence.51,52 
This index was obtained from standardised interviews by nurses at entry and at discharge. 
 
Six minute walking test. The walking test was performed in an indoor unobstructed 30 m 
long corridor, according to the American Thoracic Society recommendations.53 All patients 
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were informed in a standardized manner of the purpose and method of the test before the 
test was performed. They were instructed to walk the corridor from one end to the other at 
their own pace, as many time as possible, in the permitted time. They were advised on the 
possibility of slowing down the pace and stopping or resting as needed to resume walking 
as soon as they felt they were able to do so. After six minute had elapsed patients were 
instructed to stop walking and the total distance was measured. The test was supervised 
by a physical therapist or a physician who encouraged the patients in a standardized 
fashion at regular intervals.53 
 
Cardiopulmonary exercise test. The cardiopulmonary exercise test (CPET) was 
performed at the end of the rehabilitation period, usually on the day before discharge. The 
test was performed in the late mornings, at least 3 hours after a light meal, on a computer 
driven cycle ergometer (Cardiovit CS-200 Ergo-Spiro, Schiller AG, Baar, CH ; Ergoselect 
100 ergometer, Ergoline GmbH, Bitz, D). A progressive ramp protocol of 6 to 10 W/min 
was used, after a 1 min adaptation and warm-up period at 0 Watts, until subjective 
exhaustion or appearance of the clinical and electrocardiographic criteria for termination of 
a stress test (progressive angina, ST segment depression ≥2 mm, symptomatic 
hypotension, hypertension, major arrhytmias).54 Expired gas was collected by means of a 
tightly fitting face mask and continuously analyzed during the exercise test (Schiller 
Ganshor CS-200 Power Cube). The oxygen consumption (VO2) at the peak of the exercise 
was expressed relative to body weight (ml/Kg/min); in the text the term VO2 max is 
referred to peak VO2; the anaerobic threshold (AT) was determined non-invasively using a 
dual-method approach (both the ventilatory equivalents and the V-slope methods); the 
peak exercise capacity was expressed in Watt as maximum sustained workload (Watt-
max). The peak respiratory exchange ratio (RER max) was calculated as VCO2/VO2 at the 
peak of the exercise.55 Ventilatory response to exercise (minute ventilation per unit of 
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carbon dioxide production, VE/VCO2 slope) was calculated with the slope calculation 
option of the spreadsheet software package. The slope of circulatory efficiency (VO2/W 
slope) from rest to peak exercise in millilitres of oxygen uptake per watt of external work 
was determined by linear regression analysis. The oxygen uptake efficiency slope 
(OUES), defined as the constant a in the linear relationship between log10VE (l/min) to VO2 
(ml/min), was calculated over the entire duration of the incremental exercise (VO2 = a x 
log10VE + b). The kinetics of VO2 recovery after exercise (T½VO2, defined as the time in 
seconds elapsing during the recovery phase before oxygen uptake equals half of the 
increase in VO2 between peak effort and baseline VO2) was also analyzed.
55 
 
Follow up. In AMI patients rate of death, hospitalizations, smoke cessation, physical 
activity and adherence to pharmacological treatment were recorded at follow up (up to 5 
years, median 2 years).  
Each patient or first degree relatives were contacted by phone by a physician. Because 11 
patients (2.9%) were lost at follow-up, final population resulted to be 365 subjects. 
Informations on all-cause and cardiac mortality and occurrence of major adverse 
cardiovascular events (MACE) (new AMI, new revascularization, heart failure or stroke) 
were collected. As secondary end-points adherence to therapy and life-style changes 
(smoking cessation and physical activity defined as more than at least 3 aerobic exercise 
sessions per week, of 30 min each) were assessed. 
 
Statistical Analysis. Continuous variables normally distributed (Kolmogorov-Smirnov and 
Shapiro Wilk tests for data normality were used) were expressed as a mean ± standard 
deviation and compared using an unpaired t-test, otherwise variables were expressed with 
median and interquartile range (IQR) and compared using a Wilcoxon-Mann-Withney test. 
Categorical variables were expressed as frequencies and percentages and were 
 28 
compared between groups by a chi-squared test. The relationships between continuous 
variables were evaluated by Pearson’s correlation coefficient. Survival curves were 
calculated by the Kaplan-Meier method and  groups were compared with a log-rank test.  A 
Cox regression multivariate analysis was also performed to determine the influence of 
different factors (age>65 years, EF<40%, diabetes, ST elevation MI, chronic renal failure, 
atrial fibrillation, left bundle branch block) on all cause mortality. All reported probability 
values are two-tailed and the significance level was set at 0.05. Statistical analyses were 
performed using SPSS 18 software package (SPSS Inc, Chicago, IL,USA). 
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Results 
 
CR after TAVI 56,57 
Clinical characteristics are shown in table 1. The two groups (TAVI and sAVR) were similar 
in terms of age, gender, mean time from the valve prosthesis implantation to the CR 
beginning and the mean stay in the CR. Furthermore, no significant differences were found 
in the prevalence of hypertension, diabetes or pre-diabetes, metabolic syndrome, coronary 
artery disease and myocardial infarction history, atrial fibrillation, left ventricular ejection 
fraction, haemoglobin (Hb) values. Most patients were in NYHA class III (90%) in both 
groups. As expected, the TAVI group showed more comorbidities and a higher prevalence 
of left bundle branch block and new pace maker implantation but with a similar, extremely 
low, drop out rate compared to sAVR group (only one case per group had to be transferred 
to an acute hospital for non fatal complications). In both groups non significant change in 
weight was observed in the short term. 
A higher percentage of TAVI patients took double antiplatelet therapy (77% vs 3%, 
p<0.01) while a higher percentage of sAVR ones was on anticoagulant therapy (69% vs 
30%, p<0.01). The use of amiodarone was more frequent in the sAVR group (43% vs 
16%, p=0.01). No significant differences were found between groups in the use of beta-
blockers, as well as calcium antagonist, angiotensin-converting enzyme inhibitor, 
angiotensin II receptor antagonist, diuretics and statins use (Table 1). 
 
Autonomy evaluation. Even though, in absolute terms, sAVR patients reached a higher 
level of autonomy after CR than the TAVI ones (BI at discharge 98.3±4.3 vs 90.3±17.2, 
p=0.01), at the end of the CR period, all patients enhanced independence and mobility 
(mean BI increment 9.9±12.6, p<0.01) and were able to walk at least with the assistance of 
a stick (Table 2). 
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Change in the six minute walking test. There was a significant increase in the six 
minute walk distance at discharge compared with baseline (Δ6MWT in the entire 
population: 66.5±52.0 m, p<0.001), with no significant differences in Δ6MWT between 
groups (Table 2, Figure 1). 
 
Cardiopulmonary exercise test. A smaller percentage of patients were able to perform 
the CPET in the TAVI than in the sAVR group; in those patients who were able to 
complete the test, exercise capacity at the end of the rehabilitation programme did not 
differ significantly between groups (mean W-max 35.2±16.2 vs 42.3±12.2 W, p=0.06; 
mean peak-VO2 12.5±3.6 vs 13.9±2.7 ml/kg/min, p=0.01; Table 2, Figure 1). No significant 
differences were found between groups in the HR at exercise peak, in the rate-pressure 
product, in the VO2 and HR at anaerobic threshold, in the peak respiratory exchange ratio 
and in the minute ventilation/carbon dioxide output slope (Table 2). A correlation was 
found between the peak VO2 and the distance walked at 6MWT on discharge (r= 0.42 , 
p<0.01; Figure 2). 
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Table 1. CR after TAVI: clinical features  
 TAVI 
n=78 
sAVR 
n=80 
All 
n=158 
p
 
Clinical characteristics     
Age (yrs) 83.3±3.6 81.0±3.1 82.1±3.6 0.06 
Age [min-max] [77-89] [76-88] [76-89]  
Male sex (%) 31.7 50.0 40.0 0.10 
Hypertension (%) 95.1 94.1 94.7 0.84 
Diabetes (%) 24.4 23.5 24.0 0.93 
Pre-diabetes (%) 37.2 40.0 38.5 0.80 
Metabolic Syndrome (%) 63.4 79.4 70.7 0.13 
Coronary artery disease (%) 65.1 65.7 65.4 0.95 
Previous MI (%) 17.1 14.7 16.0 0.78 
Previous PCI (%) 31.7 2.9 18.7 <0.01 
Previous CABG (%) 14.6 2.9 9.3 0.08 
Vascular disease (%) 26.8 17.6 22.7 0.34 
Pulmonary disease (%) 30.2 2.9 17.3 <0.01 
Renal Failure (%) 27.9 14.3 21.8 0.14 
Cancer (%) 19.5 11.8 16.0 0.36 
LBBB (%) 47.5 17.6 33.8 <0.01 
Newly implanted Pace Maker (%) 12.2 2.9 8.0 0.14 
Atrial Fibrillation (%) 25.6 25.7 25.6 0.98 
BMI (kg/m
2
) 24.7±3.7 26.0±3.8 25.3±3.8 0.14 
LVEF (%) 55.9±11.3 57.2±8.5 56.7±9.8 0.55 
NYHA 2.93±0.26 2.97±0.17 2.95±0.22 0.40 
Haemoglobin at entry (g/dL) 10.3±0.9 10.2±1.0 10.2±0.9 0.33 
Stay in CR (days) 16.6±4.7 16.1±2.9 16.4±3.9 0.58 
Time implant-rehab (days) 13.3±12.5 14.2±10.8 13.7±11.7 0.55 
Drop out (n/tot) (%) 1/78 (1.3) 1/80 (1.3) 2/158 (1.3) 0.89 
Causes Arrhythmias Acute Abdomen   
     
Medication (%)     
Aspirin  95.3 74.3 85.9 <0.01 
Clopidogrel  76.7 2.9 43.6 <0.01 
Warfarin  27.9 68.6 46.2 <0.01 
ß-blockers  51.2 65.7 57.7 0.21 
Calcium antagonist 25.6 11.4 19.2 0.11 
Amiodarone 16,3 42,9 28,2 0.01 
ACE-I  51.2 51.4 51.3 0.98 
AT-II ant  23.3 14.3 19.2 0.31 
Diuretics  79.1 80.0 79.5 0.91 
Statins  76.7 62.9 70.5 0.18 
TAVI= transcatheter aortic valve implantation; sAVR= surgical aortic valve replacement; CABG= coronary artery bypass graft; PCI= 
percutaneous coronary intervention; LBBB= Left Bundle Branch Block; BMI= body mass index; LVEF=Left ventricular ejection 
fraction; NYHA= New York Heart Association; ACE-I = angiotensin-converting enzyme inhibitor; AT-II ant = angiotensin II receptor 
antagonist. Renal failure= at least moderate reduction in glomerular filtration rate (30-59 ml/min/1.73 m2) 
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Table 2. CR after TAVI: autonomy evaluation and functional status assessment  
 
 TAVI 
n=78 
sAVR 
n=80 
All 
n=158 
p
 
 
     
Barthel Index (BI)     
At entry BI 80.9±24.3 87.6±14.5 84.1±20.5 0.16 
At discharge BI 90.3±17.2 98.3±4.3 94.0±13.4 0.01 
Δ BI 9.3±12.3 10.6±13.2 9.9±12.6 0.67 
     
6MWT (n/tot) (%)
 64/78 (82)         74/80 (92) 138/158 (87)  
Basal (mt) 240.8±94.9 259.6±98.2 250.6±96.1   0.51 
Pre-discharge (mt) 272.7±107.8 294.2±100.8 283.6±104.0   0.42 
Δ6MWT (mt) 60.4±46.4 72.3±57.3 66.5±52.0   0.45 
     
CPET
 
(n/tot) (%) 48/78 (61) 60/80 (75) 108/158 (68)  
Max workload (W) 35.2±16.2 42.3±12.2 39.6±14.5 0.06 
Peak-VO2 (ml/Kg/min) 12.5±3.6 13.9±2.7 13.4±3.1 0.16 
Peak-VO2
 
(% predicted) 70.3±18.4 73.4±17.9 72.2±17.9 0.61 
HR max
 
(beat/min) 96.7±21.0 100.5±19.4 98.9±19.9 0.56 
HR max (% predicted) 70.3±14.8 73.4±14.8 72.1±14.7 0.53 
RPP
 
(mmHg·beat/min) 12913±4615 13793±4238 13436±4353 0.55 
AT HR (beat/min) 85.3±17.8 91.4±18.6 89.1±18.3 0.38 
AT VO2
 
(ml/Kg/min) 10.8±2.9 14.7±9.7 13.3±8.0 0.20 
RER max 1.04±0.1 1.08±0.1 1.06±0.1 0.22 
VE/VCO2 slope 30.0±6.4 29.8±4.4 29.9±5.1 0.89 
TAVI= transcatheter aortic valve implantation; sAVR= surgical aortic valve replacement; 6MWT= six minute walking test; Δ6MWT= 
change in the 6 min walking test (mean calculated only in those patients who performed both the baseline and pre-discharge test); 
CPET= cardiopulmonary exercise testing; Peak-VO2= peak O2 consumption; HR max= maximal heart rate; AT HR= anaerobic 
threshold heart rate; RPP= rate-pressure product; AT VO2= anaerobic threshold O2 consumption; RER max= maximal respiratory 
exchange ratio; VE/VCO2 slope= minute ventilation/carbon dioxide output slope. 
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Figure 1. CR after TAVI. Change in the distance walked at 6MWT and peak VO2 
according to TAVI and sAVR groups 
 
 
 
 
 
 
 
 
Figure 2. CR after TAVI. Correlation between the peak VO2 at CPET and the distance 
walked at 6MWT on discharge 
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CR after LVAD 58-62 
Both LVAD and CHF patients were in extremely poor general conditions. As a result of the 
selection criteria, the two groups presented similar clinical features (age, gender, the time 
interval from the index event - device implantation or acute heart failure - were comparable 
(Table 3). Left ventricular ejection fraction (LVEF) was particularly low in both groups, even 
if in LVAD group it was slightly lower. As expected, INTERMACS class (level of limitation 
according to profiles defined by the Interagency Registry for Mechanically Assisted 
Circulatory Support) was significantly lower in LVAD than in CHF cases (Table 3). All 
patients were anemic (mean Hb values at entry 9.2±1.5 g/dl, minimum 6.0 g/dL – 
maximum 11.6 g/dL, at discharge 10.2±1.5 g/dL, minimum 6.6 g/dL – maximum 12.8 
g/dL). During the CR stay (mean 18,6 ± 8,0 days, min 5 - max 40 days) 5 patients dropped 
out of the programme due to complications requiring transferral in acute care hospitals (3 
cases of major bleedings, 1 sternal wound dehiscence, 1 ictus cerebri). 
 
Exercise capacity. In the completers, at the end of the CR period all patients enhanced 
independence and mobility (mean BI increment 11.9±10.5, p<0.01) and were able to walk 
at least with the assistance of a stick. A 6MWT could be performed in 76% of LVAD 
patients with a mean increment in the distance walked of 83 ± 36 mt (p<0.05). The mean 
distance walked at 6MWT at entry was 272 ± 55 mt (min 168 – max 345 mt), at discharge 
354 ± 64 mt (min 230 – max 490 mt). 
At the cardiopulmonary exercise test (Table 3), both LVAD and CHF patients were able to 
sustain a rather poor workload: CHF patients reached a W-max of 56.6 ± 18.2 W, while 
LVAD patients reached an even lower value of 36.3 ± 9.0 W (p<0.001). Peak-VO2 was 
slightly more depressed in LVAD patients than in reference CHF cases, but the difference 
did not reach statistical significance, neither in absolute terms nor as a percentage of the 
expected values. When the peak-VO2 reached by the patients was adjusted for the 
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haemoglobin levels, the peak oxygen uptake resulted to be slightly, but not significantly 
greater in LVAD than in CHF patients. The VO2 at anaerobic threshold (AT) was similar 
between the two groups, but LVAD patients reached AT at a significantly lower workload 
than CHF cases (Table 3). 
There was a tendency towards a lower oxygen uptake efficiency slope (OUES) in LVAD 
than in CHF patients, but the difference did not reach statistical significance. The slope of 
circulatory efficiency (VO2/W slope) was similar between the two groups of patients. The 
ventilatory efficiency (VE/VCO2 slope) was also similar in the two groups (Table 3). 
During the recovery phase from ergometric stress, in the group of LVAD patients the 
kinetics of oxygen uptake recovery (T1/2VO2) was superior (p=0.04). No significant 
correlation was found between T1/2VO2 and peak-VO2 or Hb levels both for CHF patients 
(respectively: rho -0.144, p=0.568; rho -0.381, p=0.119) and LVAD-supported patients 
(respectively: rho 0.117, p=0.643; rho -0.111, p=0.660; rho 0.022, p=0.931). 
Heart rate at the peak of exercise test was higher in LVAD compared to CHF patients, 
while heart rates at 1 and 2 minutes after the end of exercise were similar (Table 3).  
 
Cardiac autonomic function. The mean and the minimum heart rate (HR) recorded 
during the 24-h ECG Holter were significantly higher in LVAD patients compared to 
controls (Table 4). Heart rate variability (HRV) parameters estimating overall (SDNN, 
Triangular Index) and slow oscillation (SDANN) autonomic activity were significantly 
depressed in LVAD patients in the early phase after device implantation (Table 4). Similar 
results were found also in the separate analysis of the day and the night periods (Table 5). 
No significant variations were found among the groups concerning HRV parameters 
estimating high frequency oscillations (RMSSD, pNN50). 
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In the analysis of circadian oscillations of HRV for individual patients, LVAD patients did 
not show significant day/night variations of any HRV parameter; the same was also 
evident for the group of CHF patients not supported by LVAD.  
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Table 3. CR after LVAD. Main clinical and CPET parameters  
 
 LVAD CHF p 
Age (years) 63.4 ± 7.4 64.6 ± 5.3 0.51 
Male (%) 81.0 83.0 0.73 
Time from index event 38.5 ± 18.3 30.3 ± 20.8 0.13 
LVEF (%) 20.3 ± 6.3 24.4 ± 4.0 0.01 
INTERMACS class 2.5 ± 0.8 4.2 ± 0.5 <0.001 
Hb levels (g/dl) 10.8 ± 1.1 12.4 ± 2.0 <0.01 
    
CPET parameters    
W-max, W 36.3 ± 9.0 56.6 ± 18.2 <0.001 
Peak-VO2, ml/kg/min 12.5 ± 3.0 13.6 ± 2.9 0.16 
Peak-VO2 percentage of expected (%) 48.8 ± 13.9 54.2 ± 15.3 0.19 
Peak-VO2 corrected by Hb, ml/kg/min 19.5 ± 4.2 18.1 ± 4.4 0.25 
AT-VO2, ml/kg/min 10.4 ± 2.5 10.9 ± 2.2 0.50 
AT-Watt, W 25.2 ± 9.6 39.9 ± 13.2 <0.001 
VO2/W slope 11.5 ± 3.8 12.0 ± 2.0 0.63 
OUES, ml/min 1124.2 ± 226.3 1280.2 ± 391.1 0.08 
VE/VCO2 slope 32.2 ± 3.6 33.9 ± 8.5 0.34 
T1/2VO2, sec 212.5 ± 62.5 261.1 ± 80.2 0.04 
RER-max 1.07 ± 0.08 1.12 ± 0.10 0.06 
Peak HR, bpm 112.4 ± 18.8 101.5 ± 16.1 0.03 
HR-1, bpm 100.8 ± 14.0 93.4 ± 13.3 0.06 
HR-2, bpm 93.4 ± 12.2 86.5 ± 13.6 0.06 
LVAD: patients with left ventricular assist device; CHF: patients with chronic heart failure; p: level of statistical significance; LVEF: 
left ventricular ejection fraction; INTERMACS class: level of limitation according to profiles defined by the Interagency Registry for 
Mechanically Assisted Circulatory Support; Hb: haemoglobin; CPET: cardiopulmonary exercise test; W-max: maximum sustained 
workload; peak-VO2: peak oxygen uptake; AT-VO2: oxygen uptake at anaerobic threshold; AT-Watt: Watts at anaerobic threshold; 
VO2/W slope: slope of circulatory efficiency (oxygen uptake/power output slope); OUES: oxygen uptake efficiency slope; VE/VCO2: 
ventilatory equivalent of carbon dioxide; T1/2VO2: kinetics of VO2 recovery after exercise; RER-max: peak respiratory exchange ratio; 
HR: heart rate; HR-1 and HR-2: heart rate 1 and 2 min after end of exercise. 
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Table 4. CR after LVAD. HRV parameters 
 
 LVAD CHF p 
HRV parameters    
Mean HR, bpm 94.6 ± 16.4 68.4 ± 10.9 <0.001 
Minimum HR, bpm 79.5 ± 8.5 55.9 ± 10.1 <0.001 
pNN50, % 6.9 ± 7.2 8.1 ± 9.5 0.61 
SDNN 53.7 ± 18.3 91.9 ± 37.1 <0.01 
RMSSD 40.7 ± 29.7 45.0 ± 36.2 0.66 
Triangular Index 6.6 ± 2.5 11.7 ± 3.9 <0.001 
SDNN Index 23.1 ± 10.7 33.5 ± 19.3 0.06 
SDANN 42.7 ± 12.4 81.1 ± 34.2 <0.001 
HRV: heart rate variability; LVAD: patients with left ventricular assist device; CHF: congestive heart failure patients; HR: heart rate; 
pNN50: proportion of successive beats with differences in NN intervals >50ms; SDNN: standard deviation of all normal RR intervals; 
RMSSD: square root of the mean square differences of successive NN intervals; SDANN: standard deviation of the 5-min average of 
NN intervals. 
 
 
 
 
Table 5. CR after LVAD. HRV parameters: day/night (D/N) 
 
 LVAD p (D/N) CHF p (D/N)  
SDNN day 48.8 ± 16.4 0.91 85.2 ± 36.1 0.82 
SDNN night 49.2 ± 19.5 86.3 ± 39.3 
RMSSD day 38.3 ± 27.0 0.16 46.9 ± 42.9 0.28 
RMSSD night 42.1 ± 30.3 41.3 ± 24.8 
SDNN Index day 21.9 ± 10.4 0.04 34.3 ± 22.9 0.79 
SDNN Index night 24.2 ± 10.0 33.6 ± 17.0 
SDANN day 37.5 ± 12.6 0.72 73.0 ± 27.9 0.73 
SDANN night 36.3 ± 13.1 74.4 ± 38.7 
See Table 4 for abbreviations 
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CR after AMI 63,64 
Baseline characteristics of the study population are reported in table 6 and 7. On the whole 
87% of the patients had a complicated AMI and 47% were incompletely revascularized. 
The median length of in-hospital stay during the acute phase before transferring to CR unit 
was 14 days (IQR 10,18 days). At admission at the CR unit, 84% of patients showed a 
NYHA functional class II or III.  No significant differences in terms of age, sex, length of 
stay in the rehabilitative unit, rate of smokers, percentage of incomplete revascularization 
and prevalence of metabolic syndrome were observed between those with LVEF<40% 
and  with LVEF>40%. Lower LVEF group showed higher rate of previous AMI (25.3% vs 
16.1%, p = 0.04), lower incidence of STEMI,  greater degree of anemia, and longer in-
hospital stay during the acute phase (Table 6). Diabetic patients were older and, as 
expected, had worse clinical conditions (Table 7). After administration of an OGTT, a 
prediabetic status was found in 54% of patients without known diabetes. Prediabetic 
patients had intermediate clinical characteristic between the normal glucose tolerance 
(NGT) group and diabetics (Table 7). 
Overall, no fatal events occurred during the CR stay (median 15 days, IQR 13,16 days). 
Four patients (1,1%) dropped out of the programme because of non-fatal complications: 2 
subjects with unstable, refractory angina and 2 with persistent arrhythmias (1 with 
complete AV block and 1 with non-sustained ventricular tachycardia). At the end of the CR 
programme, the vast majority of the patients were on aspirin, statins, beta-blockers and 
ACE inhibitors, irrespective to basal LVEF (Table 6).  
 
Exercise capacity. At the end of the rehabilitative period, in all patients a significant 
improvement in functional status, as measured by the 6MWT, was observed (Table 8-9). 
Individuals with LVEF<40% walked a shorter distance throughout the CR period, but no 
differences in term of functional recovery were found compared with patients with higher 
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LVEF (Table 8). Exercise capacity as assessed by CPET was significantly poorer in the 
subjects with LVEF<40%. As expected, these patients achieved lower maximal workload, 
rate-pressure product  and oxygen consumption both at the peak exercise and at the 
anaerobic threshold, also the VE/VCO2 slope resulted higher (Table 8). Diabetics had the 
absolute lowest exercise capacity compared to prediabetics and NGT patients. Exercise 
performance in prediabetics was intermediate compared to the other groups (Table 9, 
Figure 3). Furthermore, a prediabetic status resulted an independent predictor of the 
6MWT at discharge and the peak oxygen consumption achieved at CPET (B -0,220, 
p<0,01). 
 
Outcome. Behavioral habits. Active smoking habits at the time of the AMI were recorded 
in 32.1%. Among these subjects, 77% definitively quitted at the follow up. In the whole 
population, 73% reported to continue regular physical activity. This group showed a lower 
rate of MACE when compared to sedentary subjects (10.8% vs 22.8%, p 0.02), despite no 
difference in age between the groups (63.76±12.4 years vs 62.0±12.4 years, p=ns). 
Adherence to therapy. At the follow-up, high adherence to therapy was registered: 96.4% 
of the patients were on aspirin;  85.2% beta-blockers;  95.6% statins and  89.0% ACE-
Inhibitors or AT II antagonists (Table 6).  
Mortality and major cardiovascular events. Cardiac and all cause mortality resulted 5.0% 
and 8.0 % at 1 year and 8.0 % and 13.0 % at 5 years, respectively and resulted higher in 
older people, in those with lower LVEF, and in diabetics (Figure 4-5, Table 10). At 
multivariate analysis age>65 years, (regression coefficient B=-0.64, p=0.03), EF<40% (B= 
0.86, p<0.01) and presence of diabetes (B= -0.73, p=0.01) resulted independent predictors 
of adverse outcome. 
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Table 6. CR after AMI. Clinical features according to residual LVEF 
 LVEF < 40 
n=99 
LVEF > 40 
n=277 
All 
n=376 
p
 
Clinical characteristics     
Age (yrs) 66.1±11.6 63.7±12.5 64.4±12.3      0.11 
Male sex (%) 78.8 76.9 77.4  0.69 
STEMI (%) 51.0 67.1 62.7 <0.01 
Vessels with critical lesions (%) 
          1 
          2 
          3 
 
28.9 
23.7 
47.4 
 
33.3 
29.3 
36.2 
 
32.2 
27.9 
39.1 
 
 
0.20 
 
Vessels treated (%) 
          1 
          2 
          3 
 
48.0 
19.4 
10.2 
 
54.0 
24.3 
9.1 
 
52.4 
23.0 
9.4 
 
 
0.10 
Incomplete revascularization (%) 52.5 44.4 46.5 0.16 
Hypertension (%) 79.8 75.3 76.5 0.38 
Diabetes (%) 43.4 23.0 28.2 <0.01 
Pre-diabetes (%) 30.1 42.0 39.0 0.06 
Metabolic Syndrome (%) 72.7 69.4 70.3 0.56 
Previous MI (%) 25.3 16.1 18.5 0.04 
Previous PTCA (%) 14.3 13.9 14.0 0.91 
Previous CABG (%) 12.1 6.9 8.3 0.10 
Vascular disease (%) 21.2 6.5 10.4 <0.01 
Pulmonary disease (%) 10.1 3.7 5.4 0.01 
Renal Failure (%) 14.1 5.9 8.1 0.01 
Atrial Fibrillation (%) 9.1 5.1 6.2 0.16 
Current smoker at MI onset (%) 33.3 31.7 32.1 0.77 
NYHA class II/III (%) 45.5/47.5 53.3/22.3 51.2/29.0 <0.01 
LVEF (%) 33.8±4.9 51.7±6.9 47.0±10.2 <0.01 
BMI (kg/m
2
) 27.2±5.5 27.4±4.3 27.4±4.6 0.69 
Haemoglobin at entry (g/dL) 11.5±1.6 12.4±1.5 12.2±1.6 <0.01 
Stay in CR (days) 15 (13,17) 14 (13,16) 15 (13,16) 0.02 
Time to rehab (days) 16 (13,25) 13 (10,17) 14 (10,18) <0.01 
Drop out (n) (%) 0 (0.0) 4 (1.4) 4 (1.1) 0.23 
     
Medication (%)     
Aspirin  98.9 97.8 98.1/96.4* 0.48 
Clopidogrel  90.4 96.0 94.6 0.04 
ß-blockers  89.4 89.0 89.1/85.2* 0.92 
ACE-I  78.7 83.9 82.6/71.3* 0.26 
AT-II ant  14.9 11.7 12.5/16.4* 0.42 
Statins  98.9 97.8 98.1/95.6* 0.49 
LVEF=Left ventricular ejection fraction; STEMI=ST elevation myocardial infarction; MI=myocardial infarction; PTCA: 
percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass graft; NYHA= New York Heart Association; 
BMI= body mass index; ACE-I = angiotensin-converting enzyme inhibitor; AT-II ant = angiotensin II receptor antagonist. Renal 
failure= at least moderate reduction in glomerular filtration rate (30-59 ml/min/1.73 m2). *(At discharge/follow up). 
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Table 7. CR after AMI. Clinical features according to glucometabolic status 
 NGT 
n=107 
Pre-diabetes 
n=127 
Diabetes 
n=92 
All 
n=326 
p
 
Clinical characteristics      
Age (yrs) 59.7±12.8 64.5±12.1 67.0±10.2 63.6±12.1   <0.01 
Male sex (%) 80.4 78.7 75.0 78.2 0.65 
STEMI (%) 75.7 63.0 51.6 64.0 <0.01 
Vessels with critical lesions (%) 
          1 
          3 
 
42.9 
23.8 
 
36.5 
35.7 
 
15.6 
57.8 
 
32.7 
38.0 
 
  <0.01 
Vessels treated (%) 
          1 
          3 
 
63.6 
5.6 
 
51.6 
10.3 
 
45.1 
11.0 
 
53.7 
9.0 
 
   0.11 
Incomplete revascularization (%) 39.3 39.4 63.0 46.0 <0.01 
Hypertension (%) 68.2 76.8 88.2 77.0 <0.01 
Metabolic Syndrome (%) 45.8 84.9 93.4 73.5 <0.01 
Previous MI (%) 15.2 14.3 28.3 18.6 0.04 
Previous PTCA (%) 11.5 10.3 19.6 13.4 0.11 
Previous CABG (%) 6.7 5.6 14.1 8.4 0.06 
Vascular disease (%) 6.5 3.2 23.9 10.2 <0.01 
Pulmonary disease (%) 2.9 4.8 8.7 5.3 0.18 
Renal Failure (%) 5.7 7.3 12.0 8.1 0.25 
Atrial Fibrillation (%) 1.9 7.9 7.6 5.9 0.11 
Current smoker at MI onset (%) 38.3 31.5 27.1 32.6 0.24 
NYHA class II  (%) 
                     III (%) 
47.7 
12.1 
64.6 
19.7 
35.6 
56.7 
50.9 
27.5 
<0.01 
<0.01 
LVEF (%) 48.4±8.9 48.6±10.5 44.3±10.4 47.3±10.1 <0.01 
BMI (kg/m
2
) 26.7±3.6 27.2±4.2 29.0±5.4 27.4±4.3 <0.01 
Haemoglobin at entry (g/dL) 12.3±1.6 12.3±1.6 12.0±1.4 12.2±1.5 0.26 
Stay in CR (days) 14 (13,16) 15 (13,15) 15 (13,17) 15 (13,16) 0.01 
Time to rehab (days) 13 (10,18)       13 (9,18) 14 (11,19) 14 (10,18) 0.55 
      
Medication (%)      
Aspirin  98.1 98.4 98.9 98.4 0.92 
Clopidogrel  92.5 95.3 96.6 94.7 0.43 
ß-blockers  91.6 88.2 90.8 90.0 0.66 
ACE-I  88.8 81.9 75.9 82.6 0.06 
AT-II ant  8.4 14.2 17.2 13.1 0.17 
Statins 98.1 98.4 98.9 98.4 0.92 
Insulin therapy 0.0 0.0 61.5 17.2 <0.01 
Oral hypoglycemic agents 0.0 0.0 33.0 9.2 <0.01 
NGT=Normal glucose tolerance; STEMI=ST elevation myocardial infarction; MI=myocardial infarction; PTCA: percutaneous 
transluminal coronary angioplasty; CABG: coronary artery bypass graft; LVEF=Left ventricular ejection fraction; NYHA= New York 
Heart Association; BMI= body mass index; ACE-I = angiotensin-converting enzyme inhibitor; AT-II ant = angiotensin II receptor 
antagonist. Renal failure= at least moderate reduction in glomerular filtration rate (30-59 ml/min/1.73 m2).  
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Table 8. CR after AMI. Functional status assessment according to residual LVEF 
 
 LVEF < 40 
n=99 
LVEF > 40 
n=277 
All 
n=376 
p
 
     
6MWT 
 
    
Basal (mt) 356.5±135.7 424.2±122.5 407.5±129.1   < 0.01 
Pre-discharge (mt) 411.3±134.0 491.3±122.1 471.3±129.7   <0.01 
Δ6MWT (mt) 65.9±62.9 72.2±53.2 70.7±55.7     0.37 
     
CPET
 
     
Max workload (W) 62.7±22.3 83.1±31.2 78.2±30.6 <0.01 
Peak-VO2 (ml/Kg/min) 15.2±3.9 18.2±5.2 17.5±5.1 <0.01 
Peak-VO2
 
(% predicted) 62.6±18.2 72.2±18.8 69.9±19.1 <0.01 
HR max
 
(beat/min) 107.6±16.8 109.2±18.7 108.8±18.2 0.52 
HR max (% predicted) 70.3±10.4 69.1±10.6 69.4±10.6 0.38 
RPP
 
(mmHg·beat/min) 14664±4208 16777±4698 16265±4666 <0.01 
AT HR (beat/min) 94.5±12.5 90.7±14.7 91.6±14.3 0.05 
AT VO2
 
(ml/Kg/min) 12.1±2.5 14.0±6.3 13.5±5.6 0.02 
RER max 1.1±0.1 1.1±0.1 1.1±0.1 0.77 
VE/VCO2 slope 28.8±4.9 26.3±4.4 26.8±4.6 <0.01 
6MWT= six minute walking test; Δ6MWT= change in the 6 min walking test; CPET= cardiopulmonary exercise testing; Peak-VO2= 
peak O2 consumption; HR max= maximal heart rate; AT HR= anaerobic threshold heart rate; RPP= rate-pressure product; AT VO2= 
anaerobic threshold O2 consumption; RER max= maximal respiratory exchange ratio; VE/VCO2 slope= minute ventilation/carbon 
dioxide output slope. 
 
 
 
Table 9. CR after AMI. Functional status assessment according to glucometabolic status 
 
 NGT 
n=107 
Pre-diabetes 
n=127 
Diabetes 
n=92 
All 
n=326 
p
 
      
6MWT 
 
     
Basal (mt) 464.2±118.4 421.7±111.1 344.2±121.8 414.9±125.0   <0.01 
Pre-discharge (mt) 532.9±117.6 488.5±110.4 404.4±125.2 479.9±127.1   <0.01 
Δ6MWT (mt) 74.2±59.6 63.8±45.9 74.1±62.1 70.0±55.3     0.29 
      
CPET
 
      
Max workload (W) 88.8±35.5 80.0±27.2 66.3±24.0 79.6±30.9 <0.01 
Peak-VO2 (ml/Kg/min) 19.4±5.5 17.9±4.8 15.3±4.1 17.8±5.1 <0.01 
Peak-VO2
 
(% predicted) 72.8±18.2 73.0±20.1 64.2±18.4 70.7±19.3 <0.01 
HR max
 
(beat/min) 111.5±18.2 110.0±18.6 105.2±17.4 109.3±18.3 0.07 
HR max (% predicted) 69.7±10.3 69.9±10.6 68.8±11.3 69.6±10.7 0.78 
RPP
 
(mmHg·beat/min) 17400±4723 16715±4604 14676±4325 16465±4686 <0.01 
AT HR (beat/min) 93.0±13.3 91.3±14.0 91.0±17.0 91.8±14.5 0.64 
AT VO2
 
(ml/Kg/min) 14.5±3.8 13.3±3.4 12.0±2.9 13.4±3.6 <0.01 
RER max 1.1±0.0 1.1±0.1 1.1±0.1 1.1±0.1 0.21 
VE/VCO2 slope 26.4±5.4 26.3±3.8 27.6±4.5 26.7±4.6 0.15 
NGT=Normal glucose tolerance; 6MWT= six minute walking test; Δ6MWT= change in the 6 min walking test; CPET= 
cardiopulmonary exercise testing; Peak-VO2= peak O2 consumption; HR max= maximal heart rate; AT HR= anaerobic threshold 
heart rate; RPP= rate-pressure product; AT VO2= anaerobic threshold O2 consumption; RER max= maximal respiratory exchange 
ratio; VE/VCO2 slope= minute ventilation/carbon dioxide output slope. 
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Figure 3. CR after AMI. Functional capacity according to glucometabolic status. Maximum 
work load (A) and peak VO2 at CPET (B) 
 
 
 
 
 
 
Table 10. CR after AMI. Events at follow up according to residual LVEF (unadjusted data) 
Events (n) (%) LVEF < 40 
n=95 
LVEF > 40 
n=270 
Age > 65 
n=177 
Age < 65 
n=188 
All 
n=365 
p*
 
p
± 
        
All-cause death 15 (15.8) 13 (4.8) 25 (14.1) 3 (1.6) 28 (7.7) 0.01  <0.01 
Cardiac death 13 (13.7) 5 (1.9) 15 (8.5) 3 (1.6) 18 (4.9)  <0.01 0.02 
MACE 30 (31.6) 42 (15.6) 46 (26.0) 26 (13.8) 72 (19.7) 0.01 0.04 
Myocardial infarction 2 (2.5) 7 (2.7) 8 (5.3) 1 (0.5) 9 (2.7) 0.91 0.07 
PTCA/CABG 3 (3.8) 18 (7.0) 11 (7.2) 10 (5.4) 21 (6.2) 0.29 0.48 
Heart Failure 13 (16.3) 12 (4.7) 13 (8.6) 12 (6.5) 25 (7.4) 0.01 0.47 
Stroke 1 (1.3) 6 (2.3) 6 (3.9) 1 (0.5) 7 (2.1) 0.55 0.03 
* p between LVEF groups; ± p between age groups; MACE=Major Adverse Cardiovascular Events (Cardiac mortality, re-
infarction, new PTCA/CABG, heart failure, stroke); LVEF=Left ventricular ejection fraction; PTCA: percutaneous transluminal 
coronary angioplasty; CABG: coronary artery bypass graft 
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Figure 4. CR after AMI. All cause-mortality according to age groups (A) and left ventricular 
ejection fraction (B) 
 
 
 
 
 
 
Figure 5. CR after AMI. Risk of major adverse cardiovascular events according to 
glucometabolic status 
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Discussion 
 
CR after TAVI. This study demonstrates, for the first time, both safety and efficacy of an 
early, intensive, CR in very elderly patients after TAVI as well as after the traditional 
surgical aortic valve replacement. Actually, in spite of the training intensity, our structured 
CR programme resulted absolutely feasible with an extremely low drop-out rate and a 
satisfactory number of 6MWT performed in both groups. At the end of the rehabilitative 
period, all patients enhanced independence, mobility and functional capacity, all were able 
to walk at least with the assistance of a cane. As expected, compared to sAVR, a smaller 
percentage of TAVI patients was able to perform a 6MWT or a CPET because of their 
more compromised conditions; nevertheless, in those who were able, performances 
reached did not differ from the traditional surgery ones. 
Cardiac rehabilitation is strongly recommended for patients after cardiac surgery,2 
particularly in very elderly people due to their age-dependent comorbidities and physical 
limitations. Despite this, octogenarians are rarely referred to CR programmes and very few 
studies have selectively investigated this subgroup of patients. Scant available data 
indicates that, in over 70s, the functional impairment assessed on admission considerably 
improved by means of CR, and that elderly patients gain a functional ability increase, not 
dissimilarly from younger ones.65,66 
In our investigation, the CR programme started immediately after surgery (within the 
second week). Although in some European countries and in few Italian centres an early in-
hospital CR is applied, in the majority of rehabilitative institutions patients are generally 
referred to an out-patient CR centre after a mean of 4 to 8 weeks post-surgery.25,67 
However, Macchi et al68 showed that, in selected patients aged over 75 years who have 
undergone cardiac surgery, long-term rehabilitation outcomes are also favourable, and 
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that an early (within the second week after the operation) rehabilitation programme can be 
as effective and safe as a late one (within the fourth week).  
Even if sAVR remains the standard of care for most patients with symptomatic severe AS, 
TAVI has been increasingly recognized as a curative treatment choice. After the 
publication of several real-world registries and the pivotal PARTNER randomized trials, 
TAVI has become the standard of care for patients for whom surgical risk is prohibitive, 
and a reasonable alternative for selected operable patients with a high risk of either 
mortality or morbidity.28 
Beyond improvement of life expectancy, an important goal of TAVI in older patients is to 
enhance their functional status. Apart from age and comorbidities, severe aortic stenosis 
represent a “per se” contraindication to physical activity so that patients usually arrive at 
the operation in a very deconditioned status. 
In the literature available, very few data exist on the functional evaluation of patients after 
TAVI. Gotzmann et al69 and Bagur et al70 performed a 6MWT before and after TAVI (30 
days and 6 months respectively) showing a significant increase in the mean distance 
walked. These findings, unrelated with any structured rehabilitation, are somehow not 
surprising as after intervention there is a reduction of the aortic gradient leading to left 
ventricular unloading and to an improvement in functional capacity. 
To the best of our knowledge, no study has assessed the effect on an early, structured, 
CR programme on functional recovery after TAVI. Comparing two 6MWT (both performed 
after TAVI, pre and post-CR) we found a significant improvement in the short period 
(∆6MWT: 60.4±46.4 mt, p<0.001); even if the absolute exercise capacity evaluated by 
6MWT was quite low in the TAVI group, it was not significantly different from that found in 
the sAVR group (Table 2, Figure 1). 
The 6MWT is a simple and reliable tool for the assessment of functional capacity in CR; it 
is also reproducible and is more reflective of activities of daily life than other tests.71 Our 
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data confirm the previously reported correlation between the distance walked in the 6MWT 
and the VO2 achieved at peak exercise during a cycle ergometer test.
72,73 However, the 
data provided by the 6MWT should be considered complementary to the CPET; in fact in 
those patients capable of performing the test, the CPET can add important information 
without additional risks.74 
We found a low functional capacity as assessed by CPET, both in the sAVR and in the 
TAVI group (Table 2). This could be explained partly by the aging process itself, partly by 
the disease and comorbidities that lead to prolonged inactivity. With aging, oxidative and 
inflammatory stress and perhaps apoptosis lead to molecular and cellular changes in 
skeletal muscle, extracellular matrix, vessel wall and intravascular compartment.75 Another 
factor that could have worsened the exercise capacity is anemia. In our series a high 
prevalence of a mild grade of anemia was found, without significant differences between 
TAVI and sAVR (Haemoglobin at entry respectively: 10.3±0.9 vs 10.2±1.0g/dL, p=0.33). 
Reduced haemoglobin levels are rather frequent in CR and do not preclude functional 
recovery, as previously demonstrated in a study referring to various cardiac pathologies.76 
It is noteworthy that in those patients who were able to walk or cycle functional capacity 
was not significantly different between TAVI and sAVR patients. A possible explanation is 
that, although TAVI patients had more comorbidities than the controls, they underwent an 
indubitably less invasive procedure that could have accelerated the recovery process in 
the short period after the operation. 
 
CR after LVAD. It is known that the implantation of a mechanical circulatory support in 
patients with advanced CHF leads to an improvement of hemodynamic parameters,77,78 
whose clinical effects are visible rather early after beginning of support.79 However, scant 
data are present in the literature on effort tolerance and feasibility of an exercise training in 
patients in assistance by an axial-flow LVAD earlier than 2 months after implant, a period 
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when patients are usually discharged to their homes.80 Laoutaris et al,81 in a very little 
cohort (14 patients), reported the efficacy of a structured exercise training when the 
program began at least 6 month after LVAD implantation. To our best knowledge, the 
present study, reporting the greatest number of axial-flow LVAD cases observed so far, 
demonstrate that a structured exercise training is feasible, safe and effective in the early 
phase of circulatory support. Indeed, considering the extremely high risk cohort of patients, 
a relatively low percentage of drop out was observed. In the completers, all patients at the 
end of the program enhanced their autonomy and improved their functional capacity as 
measured by 6MWT. 
In spite of the short time elapsed since beginning circulatory assistance, a considerable 
percentage of patients, supported by LVAD due to refractory heart failure, were able to 
tolerate a sub-maximal stress test at the end of the short period of rehabilitation. This is an 
remarkable result, if we take into account that these patients were in extremely poor 
clinical conditions only a short time before, they had recently undergone major surgical 
stress and they had been bedridden for quite a long period. In spite of these constraints, 
LVAD patients were able to reach at CPET a peak-VO2 similar to that of CHF patients in 
less compromised baseline clinical conditions; particularly, there was no difference 
between the two groups concerning the percentage of expected peak-VO2, based on age, 
sex and body surface area. The peak-VO2 in our LVAD patients was also similar to that 
reported by Dimopoulos et al,82 that observed a much smaller number of axial-flow LVAD 
(7 cases) compared to 14 CHF cases. The working capacity of LVAD cases, expressed in 
terms of afforded workload (both maximum sustained workload and workload at anaerobic 
threshold), was anyway much poorer compared to the reference group of advanced CHF 
patients.  
A parameter that showed a tendency towards slightly poorer values in LVAD cases was 
the oxygen uptake efficiency slope (OUES), whose values were approximately 12% lower 
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than those observed in CHF cases. To our knowledge, this is the first report of the 
behaviour of OUES in LVAD assisted patients. OUES is an indicator of cardiovascular and 
peripheral factors that determine oxygen uptake, as well as of pulmonary factors that 
influence ventilatory response to exercise; it is linked to development of metabolic 
acidosis, physiological dead space and arterial carbon dioxide partial pressure. Differently 
from OUES, the ventilatory response to exercise (VE/VCO2 slope, a parameter linked to 
the ventilation/perfusion mismatch, and to the occurrence of lactic acidosis and 
chemoreflex activity) showed a tendency towards better results in LVAD than in CHF 
patients. Anyway the differences of the reported parameters were small and showed no 
statistically significant difference among the two groups (possibly due to the low number of 
cases), so that only speculative considerations may be drawn. The slightly shallower slope 
of the VO2/Watt slope and poorer OUES could suggest a still limited capacity of the LVAD 
patients (compared to the more stable CHF subjects) to adapt to the non-steady-state 
conditions of the ramp exercise. A reduced O2 extraction by a low mass of exercising 
muscles and impaired skeletal muscle metabolism (due to physical deconditioning), jointly 
with the inability of LVAD to raise muscle blood flow appropriately to provide O2 rapidly 
enough to satisfy muscle requirements (due to the almost fixed output of the device, in 
presence of low variations of peripheral resistances in untrained muscles), may explain the 
findings. On the other side, a decrease in pulmonary capillary pressure induced by the 
LVAD83 could have led to a reduction of lung ventilation/perfusion mismatch, with the 
resultant small reduction in the VE/VCO2 slope.  
At the end of the exercise test, LVAD patients presented peak heart rates that were higher 
than those registered in CHF patients; in spite of this, heart rates slowed in the first two 
minutes of recovery, reaching values that were not dissimilar to those of CHF cases. 
These data are somehow different from what observed by Dimopoulos et al,82 and could 
suggest a slightly quicker restoration phase in our LVAD supported cases; this behaviour 
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is in accordance with the reduced T1/2VO2 in LVAD compared to CHF. The recovery 
kinetics of oxygen consumption following maximal exercise (T½ of VO2 recovery) is a 
reproducible parameter, that is usually reported not to be significantly affected by the 
exercise level achieved and to be directly correlated with the severity of the disease in 
CHF patients.84 The tendency to a shorter T1/2VO2 observed in our LVAD patients may 
suggest a greater efficiency in the elimination of the accumulated oxygen debt, seemingly 
linked to the increased output given by the circulatory assistance. 
LVAD patients were more anaemic compared to the group of CHF controls. Anaemia is 
known to reduce effort tolerance and peak oxygen uptake in patients with chronic heart 
failure,85-87 as oxygen carrying capacity of the blood (mainly determined by the available 
Hb, and the Hb–O2 saturation/dissociation curve) is one of the four major factors 
influencing oxygen uptake during physical effort, together with the central (cardiac) 
component, regional and local distribution of peripheral blood flow, and tissue capacity of 
O2 extraction (capillary density, mitochondrial density and function, adequacy of perfusion, 
and tissue diffusion).88 When peak-VO2 was adjusted by Hb levels,
89 peak oxygen 
consumption of our LVAD patients resulted to be slightly (not significantly) greater than 
that of the reference group of CHF. Together with defective muscular mass and metabolic 
potential, anemia could have contributed to the persisting poor performance of LVAD 
patients. 
It is known that in CHF patients, cardiac dysautonomia, as assessed by the analysis of 
heart rate variability (HRV), is associated with the degree of left ventricular dysfunction.90,91 
Theoretically, after LVAD implantation the increase of the circulatory output, accompanied 
by a restoration of beta-adrenergic density and responsiveness in cardiomyocites, in 
conjunction with reversal of the myocardial receptor downregulation, should progressively 
reduce cardiac sympathetic activation, improve neuroendocrine function and normalize 
overall autonomic system activity.92-94 However, clinical studies on a possible recovery of 
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cardiac autonomic function after implantation of a LVAD are controversial.95,96 Our data 
show that in end-stage CHF patients early after a continuous-flow LVAD implantation, in 
spite of an amelioration of functional capacity, a profound autonomic derangement is still 
evident (even poorer than those found in the control group of advanced CHF patients). 
This findings could presumably explained both by a more advanced heart failure before 
device implantation and by the effects of a recent major surgery. Indeed, before the 
intervention, the patients subsequently implanted with LVAD were in terminal conditions 
and needed intensive inotropic support. Moreover, It is known that in many surgical 
interventions,97,98 humoral factors and stress-induced activation of neural mechanisms of 
autonomic cardiovascular regulation are linked to an impairment of HRV that can persist 
for variable periods of time (up to one year). 
 
CR after AMI. To our knowledge, this is the first study that has investigated, in a real world 
setting, the safety and efficacy of an early (within 2 weeks from the index event) and 
intensive (in hospital, 3 sessions daily, 6 days for week) exercise-based CR in high risk 
patients after AMI. Safety was demonstrated by the low dropout rate (only 1.1 %) and by 
the absence of major complications during the rehabilitation programme, despite the 
severe clinical profile of the patients at enrolment; efficacy by the significant improvement 
of functional capacity in the short-term, irrespective from the basal ventricular function, and 
by the high adherence to therapy and to the proposed lifestyle modifications at follow up. 
Notably, the final net consequence in the long term might be a favorable effect on 
reduction of cardiac and total mortality, which indeed resulted low in our high risk 
population. 
The safety of a structured exercise training has been widely documented in CAD patients, 
when the exercise programme, mostly extensive, started at least 1 month after the acute 
event. Vongvanich P. et al.99 registered 4 non-fatal major events (3 cardiac arrests and 1 
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AMI), in a 9-years period with only one serious complication every 67.126 hours of 
exercise per patient. More recently, Pavy and colleagues,100 analyzing data from 65 
cardiac rehabilitation centers in France, confirmed the low rate of major cardiovascular 
events during rehabilitation: 1 event every 8484 stress tests or every 49.565 hours of 
exercise and 1.3 cardiac arrests per million hours of exercise. However, still very little is 
known about the safety of an aerobic training initiated soon after AMI. In 1982, Sivarajan et 
al.46 demonstrated the safety and efficacy of an exercise programme started shortly after 
AMI (mean 4.5 days) and maintained for 3 months, on 135 patients compared to controls 
(61 patients), receiving conventional medical management. In this study, nevertheless, 
patients older than 70 years or with complicated AMI were excluded. More recently, 
Aamont et al.47 evaluated the effect of an early start in exercise training in low risk patients 
after uncomplicated AMI (14 days after the event) compared with a delayed start control 
group (4 weeks after the event). This randomized study included a small number of 
patients: 20 subjects in the first group (60.9±10.8 years old) and 19 in the second 
(57.7±9.2 years old). Exercise training was completed without complications by all 
participants and the CPET showed improvement in functional capacity in both groups after 
CR, with no differences between them. Compared to these studies, our data first 
demonstrated that a structured, in-hospital, exercise training conducted under rigorous 
medical surveillance, without delay after the clinical stabilization, with a progressive 
intensity increase, is safe also in high risk patients after a complicated AMI. 
The beneficial effects of exercise-based CR on functional capacity have been clearly 
documented in CAD patients.101,102 In our study, at the end of the 2 week rehabilitative 
period, all patients increased the distance walked (mean 6MWT gain 70.67±55.7 m, 
p<0.05). Similar results have been reported elsewhere: in this case, however, patients 
were younger, at lower risk and followed an 8 weeks extensive CR programme.103  
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Importantly, in our study, functional recovery was independent from the basal LVEF and 
glucometabolic status: in fact, patients with LVEF<40% and diabetics, despite worse 
clinical characteristics and a lower absolute functional capacity at CPET, showed a 
functional recovery similar to the controls. After OGTT administration, a high prevalence of 
abnormal glucose metabolism was found (54%). As previously demonstrated,73 our data 
confirmed that in prediabetics exercise capacity is better than diabetic but poorer than 
normoglicemic patients. 
The most important aim of a comprehensive CR is to positively modify the risk factors 
cluster, in particular smoking and physical inactivity.2,25 
In worldwide clinical records, the rate of smokers who quit definitively after an AMI varies 
from 28% to 75%.104,105 In our analysis, the rate of smoke cessation at the follow up was 
77%. These data confirms the importance of frequent and incisive counselling 
interventions, carried out by qualified professionals, supported by psychologists and 
supplemented by teaching materials. Interestingly, part of the advantage might be 
attributed to the particular timing of the educational intervention (immediately post AMI), 
when the patient is more prone to lifestyle changes, combined with the impossibility of 
smoking because of the hospitalization. 
Seventy three per cent of our patients confirmed to continue regular aerobic activity for at 
least 30 minutes, 3 times a week. To this regard, it is noteworthy that physically active 
patients showed lower incidence of MACE compared to non- or less-active patients 
(10.8% vs 22.6%, p=0.02), independently from age, confirming the beneficial effects of 
physical exercise in post AMI patients. 
According to the literature, data regarding adherence to prescribed therapies (aspirin, 
beta-blockers, ACE-I/ARB-II and statins) after AMI are discouraging. Approximately 20-
50% of patients do not follow the pharmacological prescriptions and the drugs have been 
interrupted already in the first month after AMI, with subsequent serious impact on 
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survival.106 In our study more than 90% of patients continued to take the prescribed 
medications after 5 years. Adherence depends on many factors, but the doctor-patient 
relationship plays a crucial role and lack of time by health professionals often represents a 
serious obstacle for the realization of the indispensable "therapeutic alliance" between 
patients and care givers. In this scenario, a comprehensive CR may play a fundamental 
role by reinforcing the therapeutic suggestions provided during the acute phase of the 
disease.41  
Favorable effects of CR on prognosis after AMI have been established.42-44,101 This is the 
result of life-style interventions and of positive effect of physical activity on ventricular 
remodelling and on the residual LVEF.107 A recent meta-analysis by Haykowsky et al.45 on 
1029 clinical trials confirmed that exercise training has beneficial effects on LV remodelling 
in clinically stable post-AMI patients, with the greatest benefits in increase of LVEF and 
decrease of LV end-systolic and end-diastolic volume. In a recent Italian survey on 
patients discharged from the intensive care units after AMI, all cause mortality at 30-day 
was 5.6% and 3.4% for ST elevation AMI and non ST elevation AMI patients, 
respectively.108  In the United States, Coles et al.,109 observed in 2007 a total mortality 
rates on post AMI unselected patients, of 8.9%, 16.4%, and 23.4%, at 3-month, 1-year, 
and 2-year, respectively, suggesting the need to enhance post-discharge management 
practices. Although it is difficult to compare populations with different clinical features and 
treated by  different strategies, both all-cause and cardiac mortality in our study resulted 
low, especially considering the high risk profile of the population, suggesting the particular 
beneficial effects of our CR programme.  
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Limitations and future perspectives 
These are observational, single centre, not randomized, studies. Since CR is today 
considered a class I recommendation, patient randomization could be difficult and perhaps 
not appropriate for ethical reasons. 
The studies were conducted in an in-hospital setting, where the patients began the 
rehabilitative interventions early after the acute event and followed a relatively short period 
of intensive, exercise-based CR, under strict surveillance by a team including a physician. 
This kind of programme is still relatively uncommon in Europe and in the USA, where the 
majority of patients follow longer-term, lower-intensity, outpatient rehabilitation, often 
monitored only by physiotherapists. Whether the results of these studies are applicable to 
these programmes is unknown. Furthermore, the optimal type of training, as well as the 
optimal training frequency and intensity need further investigations. 
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Conclusions 
 
Patients who underwent TAVI and LVAD implantation are characterized by a long-term 
deconditioning status. In this perspective, benefit is not automatically achieved through 
high-technology interventions and pharmacological management alone. This study have 
shown that a short-term, supervised, exercise-based CR is feasible, safe and effective in 
elderly patients after TAVI, as well as after traditional surgery, and after LVAD 
implantation. An early CR programme enhances independence, mobility and functional 
capacity and should be encouraged in these subjects.  
An early and intensive CR, based on physical activity and counselling, resulted to be safe 
and effective also in high risk patients after AMI, both in the short and in the long period. 
Indeed, a significant improvement in functional capacity in the short term - independent 
from the basal ventricular function or glucometabolic status - and a high adherence to 
therapy and to lifestyle modifications in the long term were achieved. Despite the high risk 
profile of these patients, this produced a favourable effect on cardiac and total mortality. 
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